What is VEGF?
VEGF (vascular endothelial growth factor) is a family of dimeric glycoprotein ligands that bind VEGFR receptor tyrosine kinases on vascular endothelial cells. VEGF-A binding to VEGFR2 is the central upstream signal in the most-cited BPC-157 angiogenic mechanism.
What the research literature says
VEGF is a family of five mammalian members (VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor PlGF) plus virally encoded VEGF-E. VEGF-A is the canonical angiogenic ligand binding VEGFR1 and VEGFR2; VEGF-C and VEGF-D bind VEGFR3 and are the primary lymphangiogenic ligands.
VEGF expression is induced by hypoxia via the hypoxia-inducible-factor (HIF) transcriptional response, by inflammatory cytokines, by mechanical stretch, and by tissue injury. The compound is the master upstream regulator of physiological and pathological neovascularisation and is the target of multiple FDA-approved anti-angiogenic biologics in oncology and ophthalmology contexts.
For BPC-157, the dominant published mechanism is VEGFR2 activation on the vascular endothelium with downstream Akt phosphorylation and endothelial nitric oxide synthase signalling (PMID 27847966). The receptor-engagement framing implicates the VEGF axis at the upstream end of the cascade. The Sikiric blood-vessel review consolidates the wider vascular-signalling literature (PMID 23782145).
Why this matters in research context
VEGF matters in peptide-research contexts as the upstream ligand family at the top of the BPC-157 angiogenic-mechanism cascade. The downstream readouts — VEGFR2 phosphorylation, Akt activation, eNOS-driven NO output — all derive from VEGF-axis engagement of the receptor. Researchers studying angiogenesis pharmacology should account for VEGF as the upstream regulator; pharmacological anti-VEGF blockade (with bevacizumab or related antibodies) is the standard tool for confirming the VEGF-axis contribution to an observed angiogenic response. The detailed coverage of the VEGF ligand family is in the VEGF glossary entry.
Related compounds
- BPC-157 10mg — VEGFR2-engaging angiogenic mechanism
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Seiwerth S et al. BPC 157 and blood vessels. Curr Pharm Des 2014;20(7):1121-1125. [PMID 23782145]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.